mavrilimumab (KPL-301) / CSL Behring, Kiniksa, Huadong Medicine  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
mavrilimumab (KPL-301) / Kiniksa
Kiniksa_COVID-002: Kiniksa Announces Early Evidence of Treatment Response with Mavrilimumab in 6 Patients with Severe COVID-19 Pneumonia

Recruiting
2
6
Italy
mavrilimumab (KPL-301) - Kiniksa
Kiniksa Pharmaceuticals Ltd.
Coronavirus, Severe COVID-19 Pneumonia
 
 
NCT04337216: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation

Not yet recruiting
2
10
US
Mavrilimumab
Virginia Commonwealth University
COVID-19
08/20
08/20
NCT04492514: Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation

Recruiting
2
60
US
Mavrilimumab, KPL-301, Placebo, Control
Kristin Hudock, Kiniksa Pharmaceuticals, Ltd.
COVID 19, SARS-CoV 2, Pneumonia
05/21
05/21

Download Options